foxo4-dri senolytic peptide human trial 2024 2025 Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data
Pay in 4 interest-free payments of $5.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14




